Zanzalintinib Anaplastic Thyroid Cancer Trial: NCT07470489
Phase 2 trial NCT07470489 pairs zanzalintinib with cemiplimab in BRAF wild-type anaplastic thyroid cancer; ChEMBL, ClinicalTrials.gov and DepMap data inside.
BioQ Blog
Every BioQ post about MET: real search results, sources and the query to repeat it.
Phase 2 trial NCT07470489 pairs zanzalintinib with cemiplimab in BRAF wild-type anaplastic thyroid cancer; ChEMBL, ClinicalTrials.gov and DepMap data inside.
MET dependency and drugs in one query: DepMap Chronos, ChEMBL potency, Open Targets, CIViC, TCGA and Reactome read together, with data as of 2026-11-06.